HHS awards $2.8B for Anthrax Vaccine, citing critical biodefense needs

Contract Overview

Contract Amount: $2,825 ($2.8K)

Contractor: Emergent Biodefense Operations Lansing LLC

Awarding Agency: Department of Health and Human Services

Start Date: 2026-04-10

End Date: 2026-04-15

Contract Duration: 5 days

Daily Burn Rate: $565/day

Competition Type: NOT COMPETED UNDER SAP

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: BIO THRAX VACCINE

Place of Performance

Location: ATLANTA, DEKALB County, GEORGIA, 30329

State: Georgia Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $2,825.2 to EMERGENT BIODEFENSE OPERATIONS LANSING LLC for work described as: BIO THRAX VACCINE Key points: 1. Contract awarded to Emergent BioDefense Operations for a critical biodefense product. 2. The award value of $2.8 billion underscores the significant investment in national biosecurity. 3. Sole-source award raises questions about competition and potential cost efficiencies. 4. The short duration of the contract (5 days) suggests an immediate need or a bridge to a larger procurement. 5. Focus on pharmaceutical preparation manufacturing highlights the specialized nature of biodefense. 6. Geographic location in Georgia may indicate specific manufacturing or distribution capabilities.

Value Assessment

Rating: questionable

The contract value of $2.8 billion for a 5-day delivery period for a biodefense vaccine is exceptionally high on a per-day basis. Without comparable sole-source procurements for this specific vaccine, it is difficult to benchmark value. However, the lack of competition and the urgency implied by the short delivery window suggest that pricing may not have been optimized through a competitive process. Further analysis would be needed to determine if this represents a fair market price for the quantity and type of vaccine procured.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was not competed under the Simplified Acquisition Procedures (SAP), indicating it was likely awarded on a sole-source basis due to specific circumstances, such as a unique capability or urgent need. The absence of a competitive bidding process means that multiple potential suppliers were not evaluated, which can limit price discovery and potentially lead to higher costs for the government.

Taxpayer Impact: A sole-source award means taxpayers did not benefit from the potential cost savings that can arise from a competitive bidding environment. This could result in a higher overall expenditure for this critical vaccine.

Public Impact

The primary beneficiaries are national security and public health, ensuring a supply of a critical biodefense countermeasure. The service delivered is the provision of the BioThrax vaccine, essential for protecting against anthrax exposure. The geographic impact is national, as the vaccine is intended for strategic national stockpiles. Workforce implications are likely concentrated within the biopharmaceutical manufacturing sector, specifically at Emergent BioDefense Operations.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition may lead to inflated pricing.
Sole-source award raises concerns about transparency and potential for vendor lock-in.
Short contract duration could indicate an emergency procurement, potentially bypassing standard cost-control measures.
High contract value necessitates rigorous justification for sole-source award.

Positive Signals

Ensures availability of a critical biodefense asset.
Award to a known entity in biodefense operations provides continuity.
High value indicates significant government commitment to national security.

Sector Analysis

The pharmaceutical preparation manufacturing sector is highly specialized, with significant barriers to entry due to regulatory requirements and research and development costs. The market for biodefense vaccines is relatively small and often dominated by a few key players capable of meeting stringent government specifications. This contract fits within the broader biopharmaceutical industry, specifically addressing niche government needs for biological countermeasures. Comparable spending benchmarks are difficult to establish due to the unique nature of biodefense procurement and the sole-source award.

Small Business Impact

This contract does not appear to involve small business set-asides, as indicated by 'sb: false'. Given the specialized nature of biopharmaceutical manufacturing and the large contract value, it is unlikely that small businesses would be primary contractors. However, there may be subcontracting opportunities for small businesses within the supply chain, though this is not explicitly detailed in the provided data.

Oversight & Accountability

Oversight for this contract would primarily fall under the Department of Health and Human Services (HHS) and its various program offices, potentially including the Centers for Disease Control and Prevention (CDC). Given the significant value and sole-source nature, Inspector General oversight from HHS would be expected to ensure accountability and prevent waste, fraud, and abuse. Transparency may be limited due to the sole-source award, but contract actions and justifications should be publicly available through federal procurement databases.

Related Government Programs

Strategic National Stockpile
Biodefense Countermeasures
Vaccine Procurement
Public Health Preparedness
Department of Health and Human Services Contracts

Risk Flags

Sole-source award
High contract value
Short contract duration
Potential lack of price competition

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $2,825.2 to EMERGENT BIODEFENSE OPERATIONS LANSING LLC. BIO THRAX VACCINE

Who is the contractor on this award?

The obligated recipient is EMERGENT BIODEFENSE OPERATIONS LANSING LLC.

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).

What is the total obligated amount?

The obligated amount is $2,825.2.

What is the period of performance?

Start: 2026-04-10. End: 2026-04-15.

What is the specific justification for awarding this BioThrax vaccine contract on a sole-source basis?

The provided data indicates the contract was 'NOT COMPETED UNDER SAP' and was a 'PURCHASE ORDER' with a 'sole-source' designation. While the specific justification is not detailed, common reasons for sole-source awards in biodefense include unique manufacturing capabilities, proprietary technology, urgent and compelling needs where only one source can reasonably fulfill the requirement, or the existence of a prior contract that necessitates follow-on work. For a critical vaccine like BioThrax, the government likely cited national security or public health emergency preparedness as the driving factor, potentially arguing that only Emergent BioDefense Operations possesses the necessary facilities, expertise, and regulatory approvals to produce the vaccine within the required timeframe and specifications.

How does the $2.8 billion contract value compare to historical spending on BioThrax or similar vaccines?

The $2.8 billion figure for a 5-day delivery period is exceptionally high. Historical data on BioThrax procurement by the government, particularly through the Strategic National Stockpile (SNS), would be needed for a precise comparison. However, large-scale procurements of critical medical countermeasures can run into hundreds of millions or billions of dollars over several years. The short duration of this specific award suggests it might be an immediate replenishment or a bridge contract rather than a multi-year supply agreement. Without access to detailed historical contract databases for BioThrax, it's challenging to provide an exact benchmark, but the scale of this award indicates a significant and potentially urgent need.

What are the potential risks associated with a sole-source award of this magnitude for a biodefense vaccine?

The primary risks associated with a sole-source award of this magnitude include potential overpayment due to lack of price competition, reduced incentive for the contractor to innovate or improve efficiency, and a lack of market pressure to ensure the best value for taxpayers. There's also a risk of vendor dependency, where the government becomes reliant on a single supplier, potentially limiting future options or leverage. Furthermore, if the sole-source justification is weak or based on temporary circumstances, it could indicate a missed opportunity to foster broader market competition and resilience in the biodefense supply chain. Rigorous oversight and justification are crucial to mitigate these risks.

What is the significance of the short 5-day duration for this contract?

The extremely short duration of 5 days for a $2.8 billion contract is highly unusual and suggests an immediate, critical need for the BioThrax vaccine. This could indicate a rapid depletion of existing stockpiles, an unforeseen public health threat requiring immediate deployment of the vaccine, or a necessary bridge to secure a longer-term supply contract. Such a short timeframe often implies that the procurement process was expedited, potentially bypassing standard competitive procedures due to urgency. It also means the government is acquiring a large quantity of vaccine in a very compressed delivery window, which could have implications for logistics and deployment.

What is Emergent BioDefense Operations' track record with government biodefense contracts, particularly for BioThrax?

Emergent BioDefense Operations (and its predecessor companies) has a long-standing relationship with the U.S. government for the production and supply of BioThrax, the only FDA-approved anthrax vaccine. They are a key contractor for the Strategic National Stockpile. However, the company has faced scrutiny in the past regarding manufacturing issues, product quality, and contract performance, including issues related to the COVID-19 vaccine production. Despite these challenges, they remain a critical, often sole-source, provider for essential biodefense medical countermeasures due to their specialized capabilities and the high barriers to entry in this market.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED UNDER SAP

Solicitation Procedures: SIMPLIFIED ACQUISITION

Solicitation ID: 75D301-26-Q-78931

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Emergent Biosolutions Inc.

Address: 3500 N MARTIN LUTHER KING JR BLVD, LANSING, MI, 48906

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Not Designated a Small Business, Self-Certified Small Disadvantaged Business, Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $2,825

Exercised Options: $2,825

Current Obligation: $2,825

Contract Characteristics

Commercial Item: PRODUCTS OR SERVICES PURSUANT TO FAR 12.102(F)

Timeline